SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022913
Filing Date
2022-11-08
Accepted
2022-11-08 07:43:53
Documents
80
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20220930.htm   iXBRL 10-Q 3787438
2 EX-31.1 fulc-ex31_1.htm EX-31.1 16721
3 EX-31.2 fulc-ex31_2.htm EX-31.2 20426
4 EX-32.1 fulc-ex32_1.htm EX-32.1 9203
5 EX-32.2 fulc-ex32_2.htm EX-32.2 9353
  Complete submission text file 0000950170-22-022913.txt   11733791

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fulc-20220930_cal.xml EX-101.CAL 45623
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fulc-20220930_def.xml EX-101.DEF 245125
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20220930_pre.xml EX-101.PRE 376364
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20220930_lab.xml EX-101.LAB 467980
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20220930.xsd EX-101.SCH 61354
74 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20220930_htm.xml XML 2337354
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 221367287
SIC: 2834 Pharmaceutical Preparations